Redeye concludes SSH Communications Q2’23 was in line with our estimates on top line.
Redeye views the recent news from Lifecare, which confirms a minimum operational longevity of six mo...
Redeye’s first take on the Q2 report this morning. Cellavision presented a report aligned with our l...
Atria reported Q2 EBIT of EUR 10m, 17% (EUR 2.1m) below Refinitiv consensus.
• Weak orders in Americas and EMEA... • ... plus high COGS/SG&A costs hurt profitability • Share tra...
• Net sales -13% vs. ABGSCe, adj. EBITA -13% vs ABGSCe • We lower '23e-'25e adj.
Redeyes was surprised to see the significant drop in volumes during Q2.
Redeye believes the Q1 report from Lagercrantz was strong, especially from a profit perspective, and...
• Sales in line, EBIT below - mainly on lower capitalised costs • Sequentially weaker market in Q2 •...
Ökade intäkter med operativa verksamheter som drivare Intäkterna under Q2’23 uppgick till 109,6 mkr ...
Redeye leaves a note following Faron’s recent study update from the phase I/II BEXMAB study with its...
Redeye retains its positive view on Lagercrantz following a Q1 report with 6% organic growth and str...
Yesterday evening, Azelio announced the board’s decision to file for bankruptcy as it has been unabl...
Redeye sees a mixed Q2 report from Vertiseit, with strong q/q ARR growth, while OPEX and cash flow w...
Redeye leaves a comment following Lipum’s announcement of the preliminary outcome of the rights issu...
Redeye gives a short comment on yesterday’s announcement of a CEO change in Xavi Solutions, which so...
Redeye states that the Q2 report was decent - far from the catastrophe that the recent share-price d...
Redeye provides an update in relation to Enzymatica’s Q2 2023 report.
Redeye retains its positive view of Avensia despite a soft Q2, with sales and EBIT below our expecta...
• Q2 results due on 15 August • Expected to maintain stable organic growth of 5% • We also forecast ...
